Kyverna Therapeutics
KYTX
75 hedge funds and large institutions have $136M invested in Kyverna Therapeutics in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 29 reducing their positions, and 14 closing their positions.
106,800% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $1K
91% more capital invested
Capital invested by funds: $71.4M → $136M (+$64.9M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.22% less ownership
Funds ownership: 53.7% → 52.48% (-1.2%)
5% less funds holding
Funds holding: 79 → 75 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
38% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$1.01M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$591K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$521K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$448K |
| 5 |
Jane Street
New York
|
+$444K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.27M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.23M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$496K |
| 4 |
SCM
Superstring Capital Management
New York
|
-$438K |
| 5 |
Goldman Sachs
New York
|
-$373K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
76
Superstring Capital Management
New York
| – | -$438K | -142,542 | Closed |
|
77
Marshall Wace
London,
United Kingdom
| – | -$191K | -62,057 | Closed |
|
|
YIH
78
Y-Intercept (HK)
Hong Kong
| – | -$129K | -42,025 | Closed |
|
79
Squarepoint
New York
| – | -$91.3K | -29,730 | Closed |
|
|
JG
80
Jain Global
New York
| – | -$80.6K | -26,243 | Closed |
|
|
HF
81
HRT Financial
New York
| – | -$61K | -20,171 | Closed |
|
|
QC
82
Quadrature Capital
London,
United Kingdom
| – | -$38K | -12,392 | Closed |
|
|
CFM
83
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$36.8K | -12,000 | Closed |
|
|
IC
84
IEQ Capital
Foster City,
California
| – | -$34K | -11,068 | Closed |
|
|
AC
85
AXQ Capital
Jersey City,
New Jersey
| – | -$31.9K | -10,375 | Closed |
|
|
PD
86
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$5.22K | -1,700 | Closed |
|
|
TWD
87
True Wealth Design
Akron,
Ohio
| – | -$676 | -220 | Closed |
|
88
Raymond James Financial
St Petersburg,
Florida
| – | -$580 | -189 | Closed |
|
|
EP
89
Essential Partners
Rancho Santa Fe,
California
| – | -$378 | -123 | Closed |
|
KYTX Hedge Fund Activity: Q3 2025 in Review
75 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q3 2025, worth a combined $136M — up 91% from $71.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KYTX and 10 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 18 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $1.01M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.27M.
- 75 institutional investors held Kyverna Therapeutics (KYTX) as of Q3 2025, down from 79 in Q2 2025.
- Funds reported $136M of Kyverna Therapeutics stock for Q3 2025, up 91% quarter-over-quarter.
- 10 funds opened new Kyverna Therapeutics positions in Q3 2025 and 14 closed out, a net change of -4 holders.
- The largest Kyverna Therapeutics buyer in Q3 2025 was Woodline Partners, an estimated $1.01M added.
- The largest Kyverna Therapeutics seller in Q3 2025 was T. Rowe Price Associates, an estimated $1.27M sold.
Based on aggregated 13F filings for Q3 2025.